J&J reaps the spoils from recent price hikes


Big Pharma’s price hikes don’t always translate into better sales, thanks to rebates and discounts demanded by payers. But the strategy seems to be paying off for Johnson & Johnson ($JNJ), according to one analyst.

Price increases for top-selling meds helped drive J&J to a Q1 win, Leerink analyst Geoffrey Porges said in a note to investors. At least 70-80% of the list price increases over the last 12 months “seem to be flowing through to reported sales,” Porges said. And for some meds, “the realized price was in the range of 70-90%, with some products benefiting from most or all of their list price increases,” he said.

The trend was especially apparent for J&J’s immunology franchise. The company recently hiked the price for bestseller Remicade, RA drug Simponi and psoriasis med Stelara, and that translated into higher sales of the drugs in Q1.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

J&J's standout oncology med Imbruvica also made out well thanks to price increases. In that case, “virtually 100% of price is flowing through,” Porges said, “suggesting very modest gross to net discounts.”

But not all meds reflected the trend. “Certain products in specific categories” such as HIV “had less benefit from pricing,” Porges pointed out. J&J’s prostate cancer drug Zytiga didn’t show the same increases in sales, most likely due to higher co-pays, Porges said. And diabetes med Invokana did not chart the same benefits from price increases, which isn't surprising, given the formulary competition in that field.

Leerink analysts got their numbers by looking at quarterly demand for J&J’s top products and comparing it to revenue changes and the price increases year-over-year and quarter-over-quarter.

J&J is not the only company reaping the spoils from price increases. “To the surprise of many investors, it now appears these price increases are likely to flow through to actual sales growth, with such growth more than offsetting any volume weakness in 1Q, and resulting in significant positive revenue surprises for these companies when they report 1Q results,” Porges said. Companies such as Amgen ($AMGN), Biogen ($BIIB) and Gilead ($GILD) are set to benefit from the trend, he added.

Other companies may not fare as well with their price increases, however. A recent report from the IMS Institute for Healthcare Informatics found that net price increases--retail hikes after rebates and discounts--amounted to less than 3%, on average, last year.

Related Articles:
J&J's Imbruvica, Invokana fuel Street-beating Q1 sales
J&J's new launches deliver, but overall sales fall short on hep C, strong dollar
J&J's Invokana under scrutiny in EU for potential link to toe amputations
Big investor pushes 'underperforming' J&J to step up or split up
J&J's pharma unit 'fastest-growing' in the drug business, CEO Gorsky says

Suggested Articles

Troubled Allergan is taking steps to appease investors, including bringing in a big-name biotech exec for guidance. But not everyone is impressed.

Bayer and J&J agreed to pay $775 million to wrap up about 25,000 lawsuits claiming their Xarelto anticoagulant caused severe bleeding.

The Monsanto acquisition "was and is a good idea," says Bayer chief executive, even as the company lost phase 1 of the first bellwether Roundup trial.